BTG Gains First U.S. Approval With Methotrexate Antidote Voraxaze
This article was originally published in The Pink Sheet Daily
Transatlantic specialty pharma BTG adds to its antidote portfolio with FDA approval of Voraxaze, an enzyme drug that breaks down methotrexate in patients whose kidneys are failing due to high serum levels of the chemotherapeutic. BTG also markets snake-bite therapy CroFab and DigiFab for digitalis overdose and recently licensed a late-stage drug to counter toxicity from 5-FU chemotherapy.
You may also be interested in...
BTG of Britain plans two new acquisitions, including a therapy for liver cancer that uses radioactive glass beads and a treatment for dissolving severe blood clots. The deals create an interventional medicine business with potential sales of $1 billion; BTG is funding much of the exercise through a share placement.
The agency’s report on innovative drug approvals in FY 2012 documents the successful performance metrics for the 35 novel medicines, including first-cycle review rates and on-time user fee targets, but it notes that a larger problem lies in early stages of drug discovery and development – and it thinks it can help.
In a rare application of its Medicare “new technology add-on payments” policy to drugs, the Centers for Medicare and Medicaid Services announced it will supplement reimbursement to hospitals for the oral antibiotic Deficid and methotrexate toxicity antidote Voraxaze.